CDKN2A and central nervous system neoplasm: The 2021 WHO Classification of CNS Tumors incorporates molecular criteria, including CDKN2A homozygous deletion and TERT promoter mutation, in the diagnosis of anaplastic (WHO grade 3) meningioma.